This article was originally published on http://www.clpmag.com/2019/04/seracare-develop-ngs-standards-tumor-mutational-burden-monitoring/ Under its agreement with IQN Path, SeraCare will develop, manufacture, and supply a range of highly characterized cell line genomic DNA and formalin-fixed, paraffin-embedded standards with confirmed low, mid, and high levels of mutational burden within their exome regions. Beginning in June 2019, the materials will be sent read more…